New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Editas Medicine, Inc. (EDIT) vs Prelude Therapeutics Incorporated (PRLD)
- Editas Medicine, Inc. EDIT 1.64 −4.09%
- Prelude Therapeutics Incorporated PRLD 3.23 −0.92%
Editas Medicine, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Editas Medicine, Inc. and Prelude Therapeutics Incorporated are of similar size ($263.9M and $260.5M). Editas Medicine, Inc. has the higher net margin (−145.0% vs −247.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Editas Medicine, Inc. leads on 7 and Prelude Therapeutics Incorporated on 6.
Valuation
Profitability
| Metric | EDIT | PRLD | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (151.71%) | (283.92%) | 0.00% |
| Net margin | (144.95%) | (247.12%) | 0.00% |
| Free cash flow margin | (221.15%) | (129.68%) | 0.00% |
| Return on equity | (147.44%) | (58.36%) | (51.58%) |
| Return on assets | (34.30%) | (39.45%) | (45.91%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack